Replimune Group, Inc. (NASDAQ: REPL)
$10.8300
-0.7000 ( -4.41% ) 274.6K
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Market Data
Open
$10.8300
Previous close
$11.5300
Volume
274.6K
Market cap
$848.82M
Day range
$10.5550 - $11.6340
52 week range
$4.9200 - $17.0000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
8-k | 8K-related | 14 | Mar 26, 2024 |
10-q | Quarterly Reports | 85 | Feb 08, 2024 |
8-k | 8K-related | 15 | Feb 08, 2024 |
8-k | 8K-related | 47 | Jan 08, 2024 |